The Center for Biosimilars—January 29, 2018
The Center for Biosimilars reported that the American College of Rheumatology (ACR) held its Winter Rheumatology Symposium and hosted a panel of physicians to discuss treatment options for inflammatory arthritis. HSS rheumatologist Vivian P. Bykerk, BSc, MD, FRCPC, a panelist, provided responses to the following questions: Do you lower the dose or stretch out the interval of a biologic in someone in low disease activity or remission? Is it better to reduce the dose, or to increase the dosing interval?
"Often, patients adjust their own medications and dosing intervals, so before making a change like this, the prescriber should be clear on what the patient is taking and how often they’re taking it," Dr. Bykerk said.
Read the full article at centerforbiosimilars.com